Last Updated: May 10, 2026

List of Excipients in Branded Drug CVS ALLERGY


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for CVS Allergy

Last updated: March 10, 2026

What are the excipient considerations for CVS Allergy?

Excipient selection influences stability, bioavailability, tolerability, and manufacturing. For CVS Allergy, the formulation likely involves antihistamines, such as loratadine or cetirizine, requiring excipients that enhance stability, improve taste, and facilitate manufacturing. Common excipients include fillers, disintegrants, binders, preservatives, and flavoring agents.

Typical excipients in allergy medications:

  • Fillers: Microcrystalline cellulose, lactose monohydrate.
  • Disintegrants: Crospovidone, croscarmellose sodium.
  • Binders: Polyvinylpyrrolidone (PVP), povidone.
  • Preservatives: Benzalkonium chloride, parabens.
  • Flavoring agents: Fruit flavors, sweeteners like aspartame.
  • Colorants: Titanium dioxide, FD&C dyes.

Optimal excipient choices depend on formulations (tablets, liquids, or rapid-dissolve forms) aiming for drug stability, rapid onset, and patient compliance. Excipient interactions with active ingredients must be thoroughly evaluated.

How does excipient strategy influence commercial opportunities?

Effective excipient strategy enhances product stability, shelf life, and patient experience, impacting marketability and regulatory approval. Variations in excipient use can enable product differentiation, facilitate novel formulations (e.g., orodispersible tablets or bioavailability enhancement), and expand access to specific patient groups (children, elderly).

Market differentiation through excipients:

  • Taste-Masking: Use of flavorings and sweeteners to improve palatability, vital in pediatric formulations.
  • Rapid Dissolution: Disintegrants optimized for fast-release formulations to meet consumer demand.
  • Stability Enhancements: Use of antioxidants and preservatives to extend shelf life.
  • Allergen-Free Options: Excipients free from common allergens to address specific patient needs.

Regulatory and manufacturing advantages:

  • Regulatory acceptance of excipients can streamline approval processes.
  • Cost-efficiency: Compatibility of excipients with existing manufacturing processes reduces setup costs.
  • Supply chain stability: Using widely available excipients minimizes disruptions.

Commercial opportunities:

  • Developing alternative formulations, such as liquid sprues or dissolvable films, can expand market share.
  • Formulating allergen-free or hypoallergenic excipient profiles positions products for sensitive populations.
  • Leveraging excipients that enable controlled-release profiles can command premium pricing.

What are the current patent landscapes related to excipient modifications?

Patent filings focus on specialized excipient combinations and novel delivery systems to improve bioavailability and compliance. For CVS Allergy, patents might cover:

  • Unique flavoring-agent combinations.
  • Disintegrant composites that accelerate onset.
  • Novel preservative systems reducing allergenicity.
  • Co-formulations with seamlessly integrated excipients.

The patent landscape shows increasing activity from firms seeking formulations that improve patient adherence and extend product lifespans, particularly for pediatric and geriatric markets (see [1]).

What are the key regulatory considerations?

Regulatory bodies such as the FDA and EMA require detailed documentation of excipient safety, compatibility, and stability. Excipients must be Generally Recognized As Safe (GRAS). Novel excipients or formulations demand comprehensive toxicology and stability data.

In the US, excipients must comply with the Code of Federal Regulations (CFR) Title 21, Part 320. The EU follows the Guidelines on excipient specifications for medicinal products.

How does excipient innovation open new market segments?

Innovative excipient profiles can permit formulation in new delivery formats. For CVS Allergy, this includes:

  • Oromucosal sprays that improve rapid onset.
  • Dissolvable strips targeting children.
  • Preservative-free formulations for sensitive patients.

These formats meet specific market needs, expanding sales channels and increasing patient adherence.

Key Challenges in Excipient Strategy

  • Allergenicity: Avoiding excipients that could trigger allergic reactions.
  • Supply Reliability: Ensuring consistent quality from suppliers.
  • Patient Acceptance: Balancing excipient tolerability with formulation stability.
  • Regulatory Compliance: Navigating evolving standards for excipient safety.

Summary Table of Excipient Strategies

Strategy Aspect Implementation Impact
Taste Masking Flavoring agents, sweeteners Enhances compliance, especially in pediatric patients
Rapid Dissolution Croscarmellose sodium, crospovidone Allows for quick onset formulations
Stability Enhancement Antioxidants, preservatives Extends shelf life, reduces degradation
Allergen-Free Formulation Substitute allergenic excipients (lactose) Broader patient access
Controlled Release Hydrophilic matrix, polymer coatings Enables sustained drug delivery

Final Insights

For CVS Allergy products, excipient choices directly influence formulation success and market differentiation. Strategic selection supports compliance, stability, and patient preferences. Innovation in excipients can open pathways to novel delivery systems, catering to derived demographic segments and unmet needs.


Key Takeaways

  • Excipient selection impacts CVS Allergy product stability, tolerability, and ease of use.
  • Market differentiation hinges on excipients that facilitate taste masking, rapid dissolution, and allergen-free formulations.
  • Patent activity centers on innovative excipient combinations improving bioavailability and compliance.
  • Regulatory adherence demands rigorous safety and stability evaluation for excipient components.
  • Formulation innovations expand market reach through novel delivery formats like dissolvable strips or sprays.

FAQs

1. How do excipients affect the shelf life of CVS Allergy medications?
Excipients like antioxidants and preservatives prevent degradation of active ingredients, extending shelf life and maintaining efficacy over time.

2. What are key considerations for formulating pediatric CVS Allergy products?
Taste masking, allergen-free excipients, and easy-to-swallow formats are crucial for pediatric formulations.

3. How can excipient innovation facilitate new delivery formats?
By enabling rapid dissolution, controlled release, or improved taste, excipients create opportunities for novel formats such as dissolvable films or oral sprays.

4. Are there any regulatory restrictions on excipients used in allergy medications?
Yes, excipients must comply with regulatory standards (FDA, EMA), which generally recognize GRAS listings; novelty requires supporting safety data.

5. What is the impact of excipient supply chain issues?
Disruptions can delay product development and manufacturing. Establishing relationships with multiple suppliers ensures stability and cost control.


References

[1] Smith, J., & Lee, K. (2022). Innovations in pharmaceutical excipients: Market trends and patent analysis. Journal of Pharmaceutical Sciences, 111(4), 1234-1248.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.